skip to main content
Give

Erxi Wu

Erxi Wu
Erxi Wu, PhD

Associate Professor of Pharmaceutical Sciences

Contact

Texas A&M Irma Lerma Rangel College of Pharmacy
Mail Stop 1114 159 Reynolds Medical Bldg.
College Station , TX 77843
erxiwu@tamu.edu
Phone: 254.724.3785
Fax: 254.724.5779

Education and Training

  • Harvard Medical School , Instructor in Pediatrics, 2008
  • Harvard-MIT Division of Health Sciences and Technology, Research Fellow (NLM fellowship) in Health Sciences and Technology, 2005-2007
  • Children’s Hospital Boston, Harvard Medical School Staff Scientist and faculty member, 2005-2008
  • Dana-Farber Cancer Institute, Harvard Medical School , Research Associate in Medicine, 1998-2004
  • Massachusetts Institute of Technology (MIT) , Special Graduate Student in Modern Medicine, 2007-2008
  • Sheffield University Medical School , Ph.D. students in Human Metabolism and Clinical Biochemistry, 1995-1998

Research Interests

  • Cancer (brain tumors, neuroblastoma, pancreatic cancer, etc.) therapeutics targets, cancer stem cell biology
  • Therapeutics of neurodegenerative diseases
  • Blood biomarkers in cancer and other diseases
  • Drug binding targets, drug discovery, and natural products; Pharmacogenomics

Awards, Recognition and Service

  • President, the International Association of Biological and Medical Research (IABMR), 2002-2003)
  • President, Sino-American Pharmaceutical Professional Association-New England (SAPA-NE) , 2003-2004)
  • Vice President, Sino-American Pharmaceutical Professional Association (SAPA), 2003-2004
  • Guest Editor, Special Issue (Hot Topic), Current Medicinal Chemistry, 2002-2003
  • Invited Speaker, Shanghai 2004 Bio-Forum/Tri-Conferences, 2004
  • Outstanding Leadership Award, IABMR, 2005
  • Board Director of Chinese-American BioMedical Association (CABA), 2007-present
  • Editor-in-Chief, Newsletters, Association of Chinese Americans in Cancer Research (ACACR), 2017-present
  • Pioneer Award, Chinese-American BioMedical Association 10th Annual Conference, 2017
  • Ad Hoc Reviewer for over 50 scientific journals, e.g., Science Advances, Cancer Research, etc.

Representative Publications

  • Xia Z, Wang F, Zhou S, Zhang R, Wang F, Huang JH, Wu E*, Zhang Y*, Hu Y*. Catalpol protects synaptic proteins from beta-amyloid induced neuron injury and improves cognitive functions in aged rats. Oncotarget. May 17, 2017 (*corresponding author).
  • Wang X, Zhou S, Ding X, Ma M, Zhang J, Zhou Y, Wu E*, Teng J*. Activation of ER stress and autophagy induced by TDP-43 A315T as pathogenic mechanism and the corresponding histological changes in skin as potential biomarker for ALS with the mutation. International Journal of Biological Sciences. July 2015. (*corresponding author).
  • Ding X, Ma M, Teng J, Yin J, Teng R, Zhou S, Fonkem E, Huang J, Wu E*, Wang X*. Exposure to ALS-FTD-CSF induced the formation of TDP-43 aggregates in U251 cells via exosome and TNT-like structure. Oncotarget. June 2015. (*corresponding author).
  • Li J, Ding X, Jiang W, Zhang R, Sun X, Xia Z, Wang X, Wu E*, Zhang Y*, Hu Y*. Harpagoside ameliorates the amyloid-β-induced cognitive impairment in rats via up-regulating BDNF expression and MAPK/PI3K pathways. Neuroscience. May 2015. (*corresponding author).
  • Wang X, Ma M, Teng J, Zhang J, Zhou S, Zhang Y, Wu E*, Ding X*. Chronic exposure to cerebrospinal fluid of multiple system atrophy in neuroblastoma and glioblastoma cells induces cytotoxicity via ER stress and autophagy activation. Oncotarget. April 20, 2015. (*corresponding author).
  • Wang F, Remke, Bhat K, Wong ET, Zhou S, Ramaswamy V, Dubuc A, Fonkem E, Salem S, Zhang H, Hsieh TC, O'Rourke ST, Li DW, Wu L, Hawkins C, Kohane IS, Wu M, Wu JM, Taylor MD*, Wu E*. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. (*corresponding author). Oncotarget. Dec 17, 2014
  • Li X, Wang Z, Ma Q, Xu Q, Liu H, Duan W, Lei J, Ma J, Wang X, Lv S, Han L, Li W, Guo J, Guo K, Zhang D, Wu E, Xie K. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Clinical Cancer Research. Aug 15; 20(16):4326-38. 2014.
  • Gong L, Ji WK, Hu XH, Hu WF, Tang XC, Huang ZX, Li L, Liu M, Xiang SH, Wu E, Woodward Z, Liu YZ, Nguyen QD, Li DW. Sumoylation differentially regulates Sp1 to control cell differentiation. Proceedings of the National Academy of Sciences of the United States of America. 111(15):5574-5579. 2014.
  • Guo J, Ma Z, Ma Q*, Wu Z, Fan P, Zhou X, Chen L, Zhou S, Goltzman D, Miao D, Wu E*. 1,25(OH)2D3 inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Current Medicinal Chemistry. 20(33):4131-4141. 2013 (*corresponding author).
  • Zhou S, Wang F, Wong ET, Fonkem E, Hsieh TC, Wu JM, Wu E*. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Current Medicinal Chemistry. 20(33):4095-4101. 2013 (*corresponding author).
  • Li X, Ma G, Ma Q*, Li W, Liu J, Han J, Duan W, Xu Q, Liu H, Wang Z, Sun Q, Wang F, Wu E*. Neurotransmitter substance P in nerves mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Molecular Cancer Research. 11(3):294-302. 2013 (*corresponding author).
  • Wu E*, Zhou S, Bhat K, Ma Q. CA 19-9 and pancreatic cancer. Clinical Advances in Hematology & Oncology. Invited. 11(1): 53–55. 2013 (*corresponding author).
  • Zhang G*, Wang Y, Zhang Y, Wan X, Li J, Liu K, Wang F, Liu K, Liu Q, Yang C, Yu P, Huang Y, Wang S, Jiang P, Qu Z, Luan J, Duan H, Zhang L, Hou A, Jin S, Hsieh TC, Wu E*. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Current Molecular Medicine. 12(2):163-76. 2012 (*corresponding author).
  • Bhat K, Wang F*, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E*. Advances in biomarker research for pancreatic cancer. Current Pharmaceutical Design. 18(17):2439-2451. 2012 (*corresponding author).
  • Tian Z, An N, Zhou B, Xiao P, Kohane IS, Wu E*. Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells. Cancer Chemotherapy and Pharmacology. 63 (6):1131-1139. 2009 (*corresponding author).
  • Tian Z, Shen J, Moseman AP, Yang QL, Yang JS, Xiao PG, Wu E*, Kohane IS. Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells. International Journal of Cancer. 122(1):31-8, 2008 (*corresponding author).
  • Zhang H, Bajrazzewski N*, Wu E*, Wang H, Moseman, AP, Dabora SL, Griffin JD, Kwiatkowski DJ. PDGFRs are critical for PI3K/AKT activation and negatively regulated by mTOR. Journal of Clinical Investigation. 117(3):730-738, 2007 (*equal author).
  • Wu E*. Remembering Dr. Judah Folkman, Father of angiogenesis. Trends in Bio/Pharmaceutical Industry. 2008 (*corresponding author).
  • Tian Z, Shen J, Moseman AP, Yang QL, Yang JS, Xiao PG, Wu E*, Kohane IS. Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells. International Journal of Cancer. 122(1):31-8, 2008 (*corresponding author).
  • Wu E, Mari BP, Wang F, Anderson IC, Sunday ME, Shipp MA. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. Journal of Cellular Biochemistry, 82(4):549-555. 2001.
  • For a complete list of publications click here: myncbi